XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenues:        
Royalties $ 21,931 $ 15,698 $ 60,372 $ 39,842
Material sales 7,664 4,219 14,336 13,445
License fees, milestones and other revenues 3,780 1,702 15,930 17,500
Total revenues 33,375 21,619 90,638 70,787
Operating costs and expenses:        
Cost of sales [1] 2,385 999 3,628 2,674
Amortization of intangibles 2,706 2,706 8,126 7,912
Research and development 4,759 5,898 18,254 14,813
General and administrative 7,032 6,550 20,904 20,858
Total operating costs and expenses 16,882 16,153 50,912 46,257
Income from operations 16,493 5,466 39,726 24,530
Other (expense) income:        
Interest expense, net (2,822) (3,116) (8,625) (9,172)
Increase in contingent liabilities (1,336) (958) (2,302) (2,595)
Loss from Viking (1,019) (1,396) (3,350) (14,139)
Other income, net 755 1,215 1,117 2,107
Total other expense, net (4,422) (4,255) (13,160) (23,799)
Income before income taxes 12,071 1,211 26,566 731
Income tax (expense) benefit (3,645) (160) (7,000) 28
Income from operations 8,426 1,051 19,566 759
Gain on sale of Oncology Product Line before income taxes 0 0 0 1,139
Income tax expense on discontinued operations 0 0 0 (408)
Income from discontinued operations 0 0 0 731
Net income $ 8,426 $ 1,051 $ 19,566 $ 1,490
Basic earnings per share data        
Income from continuing operations (in usd per share) [2] $ 0.40 $ 0.05 $ 0.93 $ 0.04
Income from discontinued operations (in usd per share) [2] 0.00 0.00 0.00 0.04
Net income (in usd per share) [2] 0.40 0.05 0.93 0.07
Diluted earnings per share data        
Income from continuing operations (in usd per share) [2] 0.36 0.05 0.84 0.03
Income from discontinued operations (in usd per share) [2] 0.00 0.00 0.00 0.03
Net income (USD per share) [2] $ 0.36 $ 0.05 $ 0.84 $ 0.07
Shares used for computation        
Basic (in shares) 21,071,000 20,887,000 21,007,000 20,806,000
Diluted (in shares) 23,551,245 22,997,279 23,261,857 22,742,249
[1] Excludes amortization of intangibles.
[2] The sum of net income per share amounts may not equal the totals due to rounding.